Ciliary ganglion

Orchestra BioMed Announces Upcoming Presentations on BackBeat CNT™ and Virtue® SAB at CRT 2023

Retrieved on: 
Friday, February 24, 2023
FACC, Ciliary ganglion, University, Hypertension, DES, SAB, Ohio State University, Patient, Medicine, CRT, BRS, Medical imaging, Pharmaceutical industry, HOPE

NEW HOPE, Pa., Feb. 24, 2023 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today announced that previously reported data from its BackBeat Cardiac Neuromodulation Therapy™ (CNT™) and Virtue® Sirolimus AngioInfusion™ Balloon (SAB) programs will be featured in upcoming oral presentations at the Cardiovascular Research Technologies (CRT) 2023 Meeting, which is being held in Washington, DC, from February 25 – 28, 2023.

Key Points: 
  • NEW HOPE, Pa., Feb. 24, 2023 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today announced that previously reported data from its BackBeat Cardiac Neuromodulation Therapy™ (CNT™) and Virtue® Sirolimus AngioInfusion™ Balloon (SAB) programs will be featured in upcoming oral presentations at the Cardiovascular Research Technologies (CRT) 2023 Meeting, which is being held in Washington, DC, from February 25 – 28, 2023.
  • Details on the presentations are shown below.
  • Presentation Session Time & Title: 8:00 AM – 12:00 PM ET, Renal Denervation and Hypertension Therapies
    Presenting Author: Dean Kereiakes, M.D., FACC, FSCAI, Medical Director of The Christ Hospital Heart and Vascular Center; Professor of Clinical Medicine at Ohio State University
    Presentation Session Time & Title : 2:00 PM – 5:55 PM ET, BRS, DES and DCH Technologies

SoniVie Announces successful procedure with TIVUS system on first patient enrolled for REDUCED1 Pilot study

Retrieved on: 
Wednesday, July 13, 2022
Technology, CMO, Ultrasound, Pulmonary hypertension, Renal artery, Risk, Pulmonary artery, Patient, CEO, Denervation, Blood pressure, Stroke, HTN, FDA, TEL, Kidney failure, Kaplan Medical Center, Ciliary ganglion, Respiratory disease, Chronic obstructive pulmonary disease, Pharmaceutical industry, Hypertension

TIVUS's catheter excellent ease of use and its ability to denervate at significant depth of the perivascular space allowed for a short, simple and straightforward procedure.

Key Points: 
  • TIVUS's catheter excellent ease of use and its ability to denervate at significant depth of the perivascular space allowed for a short, simple and straightforward procedure.
  • We will closely follow our patient and look forward to continuing enrolment in this exciting trial."
  • Renal Denervation with TIVUS is a minimally invasive procedure that uses high-frequency non-focused Ultra-Sound energy to ablate nerves in the renal artery.
  • "Millions of people world-wide suffer from resistant hypertension which substantially increases the risk of heart attack, stroke and kidney failure.

SoniVie receives IDE approval from FDA for its Pilot study to treat Hypertension with its Renal Artery Denervation TIVUS™ technology

Retrieved on: 
Monday, June 20, 2022
Respiratory disease, FDA, Ultrasound, Stroke, Hypertension, Technology, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Blood pressure, CEO, Company, Denervation, Renal artery, IDE, TEL, Pulmonary artery, Physician, Kidney failure, CMO, Chronic obstructive pulmonary disease, Pulmonary hypertension, Food, Patient, Ciliary ganglion, Risk, Pharmaceutical industry, Kidney

Millions of people world-wide suffer from resistant hypertension which substantially increases the risk of heart attack, stroke and kidney failure.

Key Points: 
  • Millions of people world-wide suffer from resistant hypertension which substantially increases the risk of heart attack, stroke and kidney failure.
  • The REDUCED1 study will further expand the Company's clinical experience based on two clinical trials in Renal Denervation performed using the earlier generation of the TIVUS.
  • Renal Denervation with TIVUS is a minimally invasive procedure that uses high-frequency non-focused Ultra-Sound energy to ablate nerves in the renal artery.
  • SoniVie is a medical device company developing the TIVUS, the only Ultra-Sound Denervation platform with active development programs in three therapeutic areas: pulmonary artery denervation for pulmonary hypertension, renal artery denervation for resistant hypertension, and lung denervation for chronic obstructive pulmonary disease with chronic bronchitis.

SoniVie receives IDE approval from FDA for its Pilot study to treat Hypertension with its Renal Artery Denervation TIVUS™ technology

Retrieved on: 
Monday, June 20, 2022
Respiratory disease, FDA, Ultrasound, Stroke, Hypertension, Technology, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Blood pressure, CEO, Company, Denervation, Renal artery, IDE, TEL, Pulmonary artery, Physician, Kidney failure, CMO, Chronic obstructive pulmonary disease, Pulmonary hypertension, Food, Patient, Ciliary ganglion, Risk, Pharmaceutical industry, Kidney

Millions of people world-wide suffer from resistant hypertension which substantially increases the risk of heart attack, stroke and kidney failure.

Key Points: 
  • Millions of people world-wide suffer from resistant hypertension which substantially increases the risk of heart attack, stroke and kidney failure.
  • The REDUCED1 study will further expand the Company's clinical experience based on two clinical trials in Renal Denervation performed using the earlier generation of the TIVUS.
  • Renal Denervation with TIVUS is a minimally invasive procedure that uses high-frequency non-focused Ultra-Sound energy to ablate nerves in the renal artery.
  • SoniVie is a medical device company developing the TIVUS, the only Ultra-Sound Denervation platform with active development programs in three therapeutic areas: pulmonary artery denervation for pulmonary hypertension, renal artery denervation for resistant hypertension, and lung denervation for chronic obstructive pulmonary disease with chronic bronchitis.

SyMap Medical Ltd. Announces its Strategic Collaboration with Pythagoras Medical

Retrieved on: 
Wednesday, December 29, 2021
Safety, Elation, Hypertension, Heart failure, College of Physicians & Surgeons of Mumbai, Surgeon, Arrhythmia, Denervation, CE marking, Columbia University, Multimedia, Coronavirus Scientific Advisory Board (Turkey), Dean, Ciliary ganglion, Entrepreneurship, Asthma, College, Nanjing University, Channel, RDN, Pharmaceutical industry, Physician, Pythagoras, EU

SUZHOU, China, Dec. 29, 2021 /PRNewswire/ -- SyMap Medical Ltd (SyMap) announced its strategic collaboration with Pythagoras Medical.

Key Points: 
  • SUZHOU, China, Dec. 29, 2021 /PRNewswire/ -- SyMap Medical Ltd (SyMap) announced its strategic collaboration with Pythagoras Medical.
  • With this win-win collaboration, SyMap has full rights to utilize all assets of Pythagoras, including their Renal Nerve Mapping System (ConfidenHT, CE Mark Approval,) patents, trademarks and expertise.
  • This collaboration will further enhance and consolidate the patent portfolio of SyMap and ensure the leading position of SyMap in the domain of Renal Denervation (RDN).
  • Pythagoras Medicalis a cutting-edge medical device company established by Rainbow Medical,Israel'spremier medical device investment group.

ReCor Medical Reports Latest Data from Landmark Renal Denervation Clinical Trials at TCT Annual Meeting

Retrieved on: 
Thursday, November 4, 2021
Biotechnology, General Health, Medical Devices, Health, Clinical Trials, Mortality, Safety, TCT, SOLO, Hypertension, PMA, Ciliary ganglion, Columbia University Vagelos College of Physicians and Surgeons, Medical device, Blood pressure, Tokyo Stock Exchange, Disease, TRIO, Doctor of Philosophy, BP, CE, CA, SM, Surgeon, Physician, ReCore, Patient, FDA, Pharmaceutical industry, ReCor Medical, Inc., Otsuka Medical Devices Co., Ltd., RECOR MEDICAL, INC., OTSUKA MEDICAL DEVICES CO., LTD.

Reported in a late-breaking clinical trial session at the Transcatheter Cardiovascular Therapeutics (TCT) annual meeting, patients treated with the Paradise Ultrasound Renal Denervation System maintained its blood pressure (BP) lowering effect over six months.

Key Points: 
  • Reported in a late-breaking clinical trial session at the Transcatheter Cardiovascular Therapeutics (TCT) annual meeting, patients treated with the Paradise Ultrasound Renal Denervation System maintained its blood pressure (BP) lowering effect over six months.
  • The RADIANCE-HTN TRIO study demonstrates the efficacy and 6-month safety outcomes of the Paradise Ultrasound Renal Denervation System in patients with resistant hypertension.
  • Durability of the blood pressure lowering effect of renal denervation has been a focal point for many in the field of hypertension.
  • ReCor has pioneered the minimally invasive use of ultrasound in renal denervation, and developed the Paradise System, to treat patients with hypertension.